APP and Alzheimer disease: Genetically deleting36 or pharmacologically inhibiting35,37 mGluR5 has been shown to significantly improve cognitive impairment in AD mice, as mGluR5 may function as an Aβ receptor or co-receptor with PrPC in both APP overexpression and knock-in mouse models of AD32–34.